Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females \>/=18 years old~* Adequate venous access for a minimum of 2 I.V. doses of study drug~* Acute Bacterial Skin and skin structure infection (ABSSSI) meeting at least 1 of the clinical syndrome definitions listed below and requiring I.V. antibiotic therapy. Local symptoms must have started within 7 days before the Screening Visit~  * Cellulitis/erysipelas~ * Major cutaneous abscess~ * Wound Infection~* Suspected or documented gram-positive infection from baseline Gram stain or culture.~Exclusion Criteria:~* Uncomplicated skin and skin structure infections such as furuncles, minor abscesses~* Infections associated with, or in close proximity to, a prosthetic device~* Severe sepsis or septic shock~* Known bacteremia at time of screening~* ABSSSI due to or associated with any of the following:~  * Suspected or documented gram-negative pathogens in patients with cellulitis/erysipelas or major cutaneous abscess that require an antibiotic with specific gram-negative coverage. Patients with wound infections where gram-negative adjunctive therapy is warranted may be enrolled if they meet the other eligibility criteria~ * Diabetic foot infections, gangrene, or perianal abscess~ * Concomitant infection at another site not including a secondary ABSSSI lesion (eg, septic arthritis, endocarditis, osteomyelitis)~ * Infected burns~ * Decubitus or chronic skin ulcer, or ischemic ulcer due to peripheral vascular disease (arterial or venous)~ * Any evolving necrotizing process (ie, necrotizing fasciitis)~* Use of antibiotics as follows:~  * Systemic antibiotic with gram-positive cocci activity for the treatment of any infection within 24 hours before the first infusion of study drug~ * Patients who failed prior therapy for the primary infection site are also excluded from enrollment~ * Topical antibiotic on the primary lesion within 24 hours before the first infusion of study drug except for antibiotic/antiseptic-coated dressing applied to the clean postsurgical wound~* Administration of Linezolid within 30 days before the first infusion of the study drug~* Recent history of opportunistic infections where the underlying cause of these infections is still active (eg, leukemia, transplant, acquired immunodeficiency syndrome \[AIDS\])~* Previous exposure to Tedizolid Phosphate treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tedizolid Phosphate (Sivextro, BAY119-2631) (Type: EXPERIMENTAL): Participants received 200 mg Tedizolid Phosphate once daily intravenous (I.V.) infusion to oral for 6 days, followed by 4 days of placebo.
- Linezolid (Type: ACTIVE_COMPARATOR): Participants received 600 mg Linezolid twice daily I.V. infusion to oral for 10 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).